Australia's Anteris Technologies hits over 2-mth high on receiving U.S. patent
** Shares Of Australia's Anteris Technologies AVR.AX rise
as much as 5.2% to A$23.67, their highest since Feb 10
** Stock set to mark best day since April 5, if gains hold
** Cardiac healthcare co says United States Patent And
Trademark Office has issued utility patent for co's novel
DurAVR™ transcatheter heart valve (THV)
** DurAVR™ THV is a valve designed to mimic the performance
of a healthy human heart valve
** AVR has risen 1.4% this year as of last close
(Reporting by Nausheen Thusoo in Bengaluru)
((Nausheen.Thusoo@thomsonreuters.com;))
Recent news on Anteris Technologies
See all newsBrief: Anteris Technologies Global Corp Gets French Regulatory Clearance For Duravr Paradigm Global Pivotal Trial
Anteris Technologies up as brokerages initiate coverage post-research quiet period
Brief: Anteris Technologies Says Aggregate Gross Proceeds From Offering Was $88.8 Mln
Anteris Technologies slides in Nasdaq debut after $89 mln US IPO
Brief: Anteris Technologies Prices 14.8 Mln Shares At $6.00 Per Share for U.S. IPO